MedElevator
Войти в исследования Journal of atherosclerosis and thrombosis · 2015
Association between SLCO1B1 521 T＞C and 388 A＞G Polymorphisms and Statins Effectiveness: A Meta-Analysis.
СтатьяМетаанализПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dai Rong, Feng Jing, Wang Yang, Yang Yuan, Deng Changkai, Tang Xiaojun, Zhao Yong, Zhou Hao, Zhang Fan
Аннотация
AIM: Previous studies on the association between the SLCO1B1 521 T＞C and 388 A＞G polymorphisms and statin effectiveness have been inconsistent. We performed this meta-analysis to provide a more comprehensive estimation of this issue.
METHODS: Multiple electronic literatues databases were searched on March 5th 2014. A quality assessment was performed using the Methodological Index for Non-Randomized Studies (MINORS) criteria. A meta-analysis, sub-group analysis, sensitivity analysis (RevMan 5.2), publication bias measuring and meta-regression analysis were conducted utilizing the Stata software program (version 12.0).
RESULTS: A total of 13 studies were included in the final meta-analysis, which included 7,079 participants. Overall, there was no statistically significant association in the four genetic models of hypolipidemic effect. For the 521 T＞C polymorphism, significant associations were found for the long-term effectiveness of lowering the low-density lipoprotein cholesterol (LDL-C) and in non-Asian populations in the dominant model [(CC＋TC vs. TT: mean difference (MD)=1.44, 95% CI: 0.25-2.64,p=0.02) and (CC＋TC vs. TT: MD=1.38, 95% CI: 0.28-2.49, p=0.01)], the recessive model [(CC vs. TT＋TC: MD=3.31, 95% CI: 0.09-6.54, p=0.04) and (CC vs. TT＋TC: MD=2.83, 95% CI: 0.26-5.41, p=0.03)], and the homozygote comparison [(CC vs. TT: MD=3.68, 95% CI: 0.42-6.94,p=0.03) and (CC vs. TT: MD=3.33, 95% CI: 0.67-5.99, p=0.01)], respectively. There were no significant differences for the other analyses of the 521 T＞C polymorphism or all the analyses of the 388 A＞G polymorphism.
CONCLUSIONS: The overall results suggest that the SLCO1B1 521 T＞C and 388 A＞G polymorphisms do not affect the lipid-lowering effectiveness of statins. However, allele C of the SLCO1B1 521 T＞C polymorphism leads to an attenuated effect on lowering the LDL-C in non-Asian populations and the long-term effectiveness of statin treatment.
METHODS: Multiple electronic literatues databases were searched on March 5th 2014. A quality assessment was performed using the Methodological Index for Non-Randomized Studies (MINORS) criteria. A meta-analysis, sub-group analysis, sensitivity analysis (RevMan 5.2), publication bias measuring and meta-regression analysis were conducted utilizing the Stata software program (version 12.0).
RESULTS: A total of 13 studies were included in the final meta-analysis, which included 7,079 participants. Overall, there was no statistically significant association in the four genetic models of hypolipidemic effect. For the 521 T＞C polymorphism, significant associations were found for the long-term effectiveness of lowering the low-density lipoprotein cholesterol (LDL-C) and in non-Asian populations in the dominant model [(CC＋TC vs. TT: mean difference (MD)=1.44, 95% CI: 0.25-2.64,p=0.02) and (CC＋TC vs. TT: MD=1.38, 95% CI: 0.28-2.49, p=0.01)], the recessive model [(CC vs. TT＋TC: MD=3.31, 95% CI: 0.09-6.54, p=0.04) and (CC vs. TT＋TC: MD=2.83, 95% CI: 0.26-5.41, p=0.03)], and the homozygote comparison [(CC vs. TT: MD=3.68, 95% CI: 0.42-6.94,p=0.03) and (CC vs. TT: MD=3.33, 95% CI: 0.67-5.99, p=0.01)], respectively. There were no significant differences for the other analyses of the 521 T＞C polymorphism or all the analyses of the 388 A＞G polymorphism.
CONCLUSIONS: The overall results suggest that the SLCO1B1 521 T＞C and 388 A＞G polymorphisms do not affect the lipid-lowering effectiveness of statins. However, allele C of the SLCO1B1 521 T＞C polymorphism leads to an attenuated effect on lowering the LDL-C in non-Asian populations and the long-term effectiveness of statin treatment.